Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00169091 · ClinicalTrials.gov registry record · Phase 4
Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia
A Phase 4 study, sponsored by Harvard Medical School (HMS and HSDM).
- Terminated
- Registry status
- Phase 4
- Development phase
- 32
- Enrollment target
NCT00169091 is a Phase 4 study that was terminated before completion, run by Harvard Medical School (HMS and HSDM). The registered enrollment target is 32 participants.
The verdict
NCT00169091, a Phase 4 study, was terminated before completion, sponsored by Harvard Medical School (HMS and HSDM).
- TERMINATED
- Registry status
- Phase 4
- Development phase
- 32 participants
- Enrollment target
Study Summary
This study will examine the physical responses brought on by clozapine and haloperidol in people experiencing their first episode of schizophrenia.
Interventions
- DRUG Haloperidol
- DRUG Clozapine
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 32 participants |
| Start Date | 1996-03 |
| Est. Completion | 2003-10 |
| Phase | Phase 4 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00169091
The ClinicalTrials.gov registry entry for NCT00169091 describes a study currently listed as terminated, categorized as Phase 4. The registered enrollment target is 32 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Harvard Medical School (HMS and HSDM), which has 26 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Haloperidol is the first listed.
NCT00169091 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00169091 about?
NCT00169091 is a clinical study titled "Clozapine Versus Haloperidol for Treating the First Episode of Schizophrenia". This study will examine the physical responses brought on by clozapine and haloperidol in people experiencing their first episode of schizophrenia.
What is the current status of trial NCT00169091?
This trial is currently terminated. It is a Phase 4 study. The enrollment target is 32 participants. The study started on 1996-03. Estimated completion is 2003-10.
What interventions are being tested in trial NCT00169091?
The interventions under investigation include: Haloperidol (DRUG), Clozapine (DRUG).
Who is sponsoring clinical trial NCT00169091?
This trial is sponsored by Harvard Medical School (HMS and HSDM), which has 26 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.